WebAug 11, 2024 · Aug 11, 2024 Victoria Johnson PBFT02, developed by Passage Bio, is delivered via intra cisterna magna administration to the brain. Passage Bio has dosed the first patient with frontotemporal dementia with granulin mutations (FTD-GRN) with their gene therapy PBFT02 in the phase 1/2 upliFT-D study (NCT04747431). WebPassage Bio is conducting two interventional studies to bring potential treatments to patients and families affected by rare CNS disorders. We Are Evaluating A New Gene …

Press Releases and Statements - Passage Bio

WebDec 10, 2024 · At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace … WebJan 22, 2024 · The U.S. Food and Drug Administration and U.K. Medicines and Healthcare products Regulatory Agency have both cleared Passage Bio to start a clinical trial for PBGM01 for infantile GM1... shopkin color sheets

A Study of PBFT02 in Patients With Frontotemporal …

WebApr 1, 2024 · PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing … WebFeb 8, 2024 · Passage Bio expects to initiate a Phase1/2 clinical trial for PBKR03 in the first half of 2024. The trial is designed as a dose escalation study of a single ICM dose of … WebDec 7, 2024 · At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. shopkin coloring page printable